

FILE 'HOME' ENTERED AT 09:20:52 ON 23 OCT 2008

=> file polymer medline mebase biosis
'MEBASE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):embase
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'APOLLIT' ENTERED AT 09:21:27 ON 23 OCT 2008

COPYRIGHT (c) 2008 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 09:21:27 ON 23 OCT 2008

COPYRIGHT (c) 2008 Elsevier Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 09:21:27 ON 23 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 09:21:27 ON 23 OCT 2008

COPYRIGHT (c) 2008 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CIN' ENTERED AT 09:21:27 ON 23 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 09:21:27 ON 23 OCT 2008

Compendex Compilation and Indexing (C) 2008

Elsevier Engineering Information Inc (EEI). All rights reserved.

Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'DISSABS' ENTERED AT 09:21:27 ON 23 OCT 2008

COPYRIGHT (C) 2008 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 09:21:27 ON 23 OCT 2008

COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 09:21:27 ON 23 OCT 2008

COPYRIGHT (C) 2008 IFI CLAIMS(R) Patent Services (IFI)

FILE 'NTIS' ENTERED AT 09:21:27 ON 23 OCT 2008

Compiled and distributed by the NTIS, U.S. Department of Commerce.

It contains copyrighted material.

All rights reserved. (2008)

FILE 'PASCAL' ENTERED AT 09:21:27 ON 23 OCT 2008

Any reproduction or dissemination in part or in full,

by means of any process and on any support whatsoever

is prohibited without the prior written agreement of INIST-CNRS.

COPYRIGHT (C) 2008 INIST-CNRS. All rights reserved.

FILE 'PROMT' ENTERED AT 09:21:27 ON 23 OCT 2008

COPYRIGHT (C) 2008 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 09:21:27 ON 23 OCT 2008
COPYRIGHT (C) 2008 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 09:21:27 ON 23 OCT 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'TEXTILETECH' ENTERED AT 09:21:27 ON 23 OCT 2008
COPYRIGHT (C) 2008 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 09:21:27 ON 23 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 09:21:27 ON 23 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:21:27 ON 23 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIFV' ENTERED AT 09:21:27 ON 23 OCT 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'WPINDEX' ENTERED AT 09:21:27 ON 23 OCT 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'WSCA' ENTERED AT 09:21:27 ON 23 OCT 2008
COPYRIGHT (C) 2008 PAINT RESEARCH

FILE 'WTEXTILES' ENTERED AT 09:21:27 ON 23 OCT 2008
COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'MEDLINE' ENTERED AT 09:21:27 ON 23 OCT 2008

FILE 'EMBASE' ENTERED AT 09:21:27 ON 23 OCT 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 09:21:27 ON 23 OCT 2008
Copyright (c) 2008 The Thomson Corporation

=> s osteoarthritis
L1 188644 OSTEOARTHRITIS

=> s 11 and treat?
18 FILES SEARCHED...
L2 95540 L1 AND TREAT?

=> s 13 and (inulin or gellan or pullulan or curdlan or alginic or laminarin or pectin)
L3 NOT FOUND
The L-number entered could not be found. To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (>).

=> s 12 and (inulin or gellan or pullulan or curdlan or alginic or laminarin or pectin)
20 FILES SEARCHED...
L3 7928 L2 AND (INULIN OR GELLAN OR PULLULAN OR CURDLAN OR ALGINIC OR LAMINARIN OR PECTIN)

=> s 13 and (sulfate or sulphate)
20 FILES SEARCHED...

L4 6519 L3 AND (SULFATE OR SULPHATE)

=> s 14 and (sodium(a)salt)
L5 1408 L4 AND (SODIUM(A) SALT)

=> s 13 and (polysulfate or polysulphate)
L6 132 L3 AND (POLYSULFATE OR POLYSULPHATE)

=> s 15 and (sodium(a)salt)
L7 1408 L5 AND (SODIUM(A) SALT)

=> s 16 and (sodium(a)salt)
L8 42 L6 AND (SODIUM(A) SALT)

=> dis 16 1-42 bib abs

L6 ANSWER 1 OF 132 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1004529 CAPLUS <<LOGINID::20081023>>
DN 143:299104
TI Use of sulfated polysaccharides for treatment of arthrosis
IN Vila Pahí, Francisco Javier; Escaich Ferrer, Josep; Verbruggen, August
 Lodewijk; Verges Milano, Josep; Ruhi, Roura Ramon; Alaez Verson, Carlos
 Raul
PA Bioiberica, S.A., Spain
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005084610	A2	20050915	WO 2005-EP1390	20050211
WO 2005084610	A3	20051208		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, NZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2251289	A1	20060416	ES 2004-464	20040227
ES 2251289	B1	20070701		
AU 2005218729	A1	20050915	AU 2005-218729	20050211
CA 2555616	A1	20050915	CA 2005-2555616	20050211
JP 2007523925	T	20070823	JP 2007-500092	20050211
EP 1917018	A2	20080507	EP 2005-707336	20050211
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20080051350	A1	20080228	US 2006-590311	20060823
PRAI ES 2004-464	A	20040227		
WO 2005-EP1390	W	20050211		
AB The present invention relates to the use of a sulfated polysaccharide in acid form or as a physiol. acceptable salt thereof, selected from the group consisting of inulin sulfate, gellan sulfate, pullulan sulfate, curdlan sulfate, alginic acid sulfate, laminarin sulfate, and pectin sulfate, for the preparation of a medicament for the treatment or prophylaxis				

of arthrosis in a mammal. Preferably, the sulfated polysaccharide is inulin sulfate, most preferably inulin polysulfate sodium salt. The present invention also relates to the use of a sulfated oligosaccharide derived from a polysaccharide selected from the group consisting of inulin, gellan, pullulan, curdlan, alginic acid, laminarin, and pectin, for the preparation of a medicament for the treatment or prophylaxis of arthrosis in a mammal. For example, inulin polysulfate sodium salt was synthesized by reacting 88 mL (1.32 mol; 1.8 equiv/OH) of chlorosulfonic acid in pyridine with 40 g (0.25 mol) inulin at 100°, and treatment with 10% sodium acetate methanolic solution. The effectiveness of the inulin polysulfate in the production of aggrecans associated with inflammation and catabolism of human chondrocytes was demonstrated in vitro. There was a dose-effect relationship, with greater doses of the compound, there was a greater increase in the production of aggrecans associated with the cells. Inulin polysulfate was also capable of reducing the aggrecan degradation in a chondrocyte culture.

L6 ANSWER 2 OF 132 USPATFULL on STN
AN 2008:298824 USPATFULL <>LOGINID::20081023>>
TI Triazole derivatives which are Smo antagonists
IN Balkovec, James M., Martinsville, NJ, UNITED STATES
Thieringer, Rolf, Highland Park, NJ, UNITED STATES
Waddell, Sherman T., Westfield, NJ, UNITED STATES
PI US 20080262051 A1 20081023
AI US 2008-82933 A1 20080415 (12)
PRAI US 2007-925018P 20070418 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ, 07065-0907, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1431
AB The present invention provides a method for the treatment or prevention of conditions which can be ameliorated by Smo antagonism, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula I or a composition comprising a compound of formula I:

#STR1##

or a pharmaceutically acceptable salt or solvate thereof; wherein:
2 of X, Y and Z represent nitrogen atoms, and the other represents an oxygen atom;
R.sup.1 and R.sup.2 are taken together with the atom to which they are attached and represent a cyclobutyl ring, optionally substituted with 1-2 fluorine atoms, and R.sup.3 represents hydrogen or a fluorine atom;
or
R.sup.1 represents methyl,
R.sup.2 represents methyl or a fluorine atom and
R.sup.3 represents a fluorine atom.

L6 ANSWER 3 OF 132 USPATFULL on STN
AN 2008:277106 USPATFULL <>LOGINID::20081023>>
TI Methods of Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisindoline-1,3-Dione
IN Muller, George W., Bridgewater, NJ, UNITED STATES

Schafer, Peter H., Somerset, NJ, UNITED STATES
Man, Hon-Wah, Princeton, NJ, UNITED STATES
Ge, Chuansheng, Belle Mead, NJ, UNITED STATES
PA Celgene Corporation (U.S. corporation)
PI US 20080242719 A1 20081002
AI US 2008-98379 A1 20080404 (12)
RLI Division of Ser. No. US 2005-170308, filed on 28 Jun 2005, Pat. No. US 7358272 Division of Ser. No. US 2003-392195, filed on 19 Mar 2003, Pat. No. US 6962940
PRAI US 2002-366515P 20020320 (60)
US 2003-438450P 20030107 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1797
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisindoline-1,3-dione, substantially free of its (-) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF- α or the inhibition of PDE4.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 132 USPATFULL on STN
AN 2008:277081 USPATFULL <>LOGINID::20081023>>
TI Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
IN D'Sidocky, Neil R., Carewood, OH, UNITED STATES
Harris, Roy L., San Diego, CA, UNITED STATES
Hegde, Sayee G., San Diego, CA, UNITED STATES
Hilgraf, Robert, San Diego, CA, UNITED STATES
McCarrick, Margaret A., San Diego, CA, UNITED STATES
McKie, Jeffrey A., San Marcos, CA, UNITED STATES
Mortensen, Deborah S., San Diego, CA, UNITED STATES
Nadolny, Lisa, San Diego, CA, UNITED STATES
Perin-Ninkovic, Sophie M., Carlsbad, CA, UNITED STATES
Sapienza, John J., Chula Vista, CA, UNITED STATES
Wright, Jonathan L., San Diego, CA, UNITED STATES
PI US 20080242694 A1 20081002
AI US 2007-901598 A1 20070917 (11)
PRAI US 2006-845558P 20060918 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6051
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided herein are Heterocyclic Compounds having the following structure:

#STR1#

wherein R.sup.1, R.sup.2, X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 132 USPATFULL on STN
AN 2008:268191 USPATFULL <>LOGINID::20081023>>
TI Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
IN Muller, George W., Bridgewater, NJ, UNITED STATES
Schafer, Peter H., Somerset, NJ, UNITED STATES
Man, Hon-Wah, Princeton, NJ, UNITED STATES
Ge, Chuansheng, Belle Mead, NJ, UNITED STATES
Xu, Jean, Warren, NJ, UNITED STATES
PI US 20080234359 A1 20080925
AI US 2008-79615 A1 20080327 (12)
RLI Continuation-in-part of Ser. No. US 2005-106142, filed on 13 Apr 2005, PENDING Division of Ser. No. US 2003-392195, filed on 19 Mar 2003, Pat. No. US 6962940
PRAI US 2002-366515P 20020320 (60)
US 2003-438450P 20030107 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN 33 Drawing Page(s)
LN.CNT 3543

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Solid forms comprising (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their use are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF- α or the inhibition of PDE4.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 132 USPATFULL on STN
AN 2008:261162 USPATFULL <>LOGINID::20081023>>
TI 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
IN HUTCHINSON, John H., La Jolla, CA, UNITED STATES
PRASIT, Petpiboon Peppi, Rancho Santa Fe, CA, UNITED STATES
MORAN, Mark, Orinda, CA, UNITED STATES
EVANS, Jillian F., San Diego, CA, UNITED STATES
ZUNIC, Jasmine Eleanor, San Diego, CA, UNITED STATES
STOCK, Nicholas Simon, San Diego, CA, UNITED STATES
PA AMIRA PHARMACEUTICALS, INC., San Diego, CA, UNITED STATES (U.S. corporation)
PI US 20080227807 A1 20080918
AI US 2008-131828 A1 20080602 (12)
RLI Division of Ser. No. US 2006-538762, filed on 4 Oct 2006, Pat. No. US 7405302
PRAI US 2005-725573P 20051011 (60)

DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA,
94304-1050, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 5391

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 132 USPATFULL on STN
AN 2008:246647 USPATFULL <<LOGINID::20081023>>
TI N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
IN Muller, George W., Bridgewater, NJ, UNITED STATES
Chen, Roger Shen-Chu, Edison, NJ, UNITED STATES
PI US 20080214615 A1 20080904
AI US 2007-901291 A1 20070914 (11)
PRAI US 2006-845227P 20060915 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3525

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to N-methylaminomethyl-isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 132 USPATFULL on STN
AN 2008:239040 USPATFULL <<LOGINID::20081023>>
TI Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminooisoindoline 1,3-dione
IN Muller, George W., Bridgewater, NJ, UNITED STATES
Schafer, Peter H., Somerset, NJ, UNITED STATES
Man, Hon-Wah, Princeton, NJ, UNITED STATES
Ge, Chuansheng, Belle Mead, NJ, UNITED STATES
PA Celgene Corporation (U.S. corporation)
PI US 20080207730 A1 20080928
AI US 2008-69282 A1 20080208 (12)
RLI Division of Ser. No. US 2005-170308, filed on 28 Jun 2005, Pat. No. US 7358272 Division of Ser. No. US 2003-392195, filed on 19 Mar 2003, Pat. No. US 6962940
PRAI US 2002-366515P 20020320 (60)
US 2003-438450P 20030107 (60)
DT Utility
FS APPLICATION

LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1794

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (-) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF- α or the inhibition of PDE4.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 132 USPATFULL on STN
AN 2008:238980 USPATFULL <>LOGINID::20081023>>
TI (S)-N-Stereoisomers of 7,8-Saturated-4,5-Epoxy-Morphinanum Analogs
IN Perez, Julio, Tarrytown, NY, UNITED STATES
Han, Amy Qi, Hockessin, DE, UNITED STATES
Rotshteyn, Yakov, Monroe, NY, UNITED STATES
PA Progenics Pharmaceuticals, Inc., Tarrytown, NY, UNITED STATES (U.S. corporation)
PI US 20080207669 A1 20080828
AI US 2007-944242 A1 20071121 (11)
PRAI US 2006-867101P 20061122 (60)
US 2006-867394P 20061127 (60)
DT Utility
FS APPLICATION
LREP KELLEY DRYE & WARREN LLP, 400 ATLANTIC STREET , 13TH FLOOR, STAMFORD, CT, 06901, US
CLMN Number of Claims: 63
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 4224

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel (S)-N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanum analogs are disclosed. Pharmaceutical compositions containing the (S)-N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanum analogs and methods for their pharmaceutical uses are also disclosed. Such analogs are disclosed as being useful in treating, among varying conditions, hypermotility of the gastrointestinal tract.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 132 USPATFULL on STN
AN 2008:221598 USPATFULL <>LOGINID::20081023>>
TI 4-Biaryl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia
IN Martinez, Eduardo J., St. Louis, MO, UNITED STATES
Talley, John Jeffrey, Somerville, MA, UNITED STATES
Lundrigan, Regina, Charlestown, MA, UNITED STATES
PA MICROBIA, INC., Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 20080194494 A1 20080814
AI US 2006-912558 A1 20060426 (11)
WO 2006-US15814 20060426
20080311 PCT 371 date
PRAI US 2005-674729P 20050426 (60)

DT Utility
FS APPLICATION
LREP HESLIN ROTHENBERG FARLEY & MESITI PC, 5 COLUMBIA CIRCLE, ALBANY, NY,
12203, US
CLMN Number of Claims: 79
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7159

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a chemical genus of
4-biaryl-1-phenylazetidin-2-ones useful for the treatment of
hypercholesterolemia and other disorders, having general formula:

##STR1##

Pharmaceutical compositions and methods for treating
cholesterol- and lipid-associated diseases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 132 USPATFULL on STN
AN 2008:201878 USPATFULL <>LOGINID::20081023>>
TI Triazole compounds that modulate Hsp90 activity
IN Sun, Lijun, Harvard, MA, UNITED STATES
Ying, Weiwen, Ayer, MA, UNITED STATES
Chae, Junghyun, Youngdengpo-gu, KOREA, REPUBLIC OF
Przewloka, Teresa, Tewksbury, MA, UNITED STATES
Zhang, Shijie, Nashua, NH, UNITED STATES
Chimmanamada, Dinesh U., Waltham, MA, UNITED STATES
Foley, Kevin, Waltham, MA, UNITED STATES
Du, Zhenjian, Northborough, MA, UNITED STATES
Li, Hao, Brookline, MA, UNITED STATES
James, David, Cambridge, MA, UNITED STATES
Ng, Howard P., Belmont, MA, UNITED STATES
Demko, Zachary, Somerville, MA, UNITED STATES
Zhou, Dan, Lexington, MA, UNITED STATES
Qin, Shuzhen, West Roxbury, MA, UNITED STATES
PA Synta Pharmaceuticals Corp (U.S. corporation)
PI US 20080176840 A1 20080724
AI US 2007-807327 A1 20070525 (11)
PRAI US 2006-808276P 20060525 (60)
US 2006-808253P 20060525 (60)
US 2006-808284P 20060525 (60)
US 2006-808255P 20060525 (60)
US 2006-808339P 20060525 (60)

DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
9133, CONCORD, MA, 01742-9133, US
CLMN Number of Claims: 69
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 13115

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to substituted triazole compounds and
compositions comprising substituted triazole compounds. The invention
further relates to methods of inhibiting the activity of Hsp90 in a
subject in need thereof and methods for preventing or treating
hyperproliferative disorders, such as cancer, in a subject in need
thereof comprising administering to the subject a substituted triazole
compound of the invention, or a composition comprising such a compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 132 USPATFULL on STN
AN 2008:190943 USPATFULL <>LOGINID::20081023>>
TI Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP)
inhibitors
IN Jones, Philip, Pomezia, ITALY
Ontoria Ontoria, Jesus Maria, Pomezia, ITALY
Scarpelli, Rita, Pomezia, ITALY
Schultz-Fademrecht, Carsten, Pomezia, ITALY
PI US 20080167345 A1 20080710
AI US 2008-6993 A1 20080108 (12)
PRAI GB 2007-432 20070110
US 2007-921310P 20070402 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ, 07065-0907, US
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2413
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of formula I:

#STR1##

and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- and/or radiosensitizers for cancer treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 132 USPATFULL on STN
AN 2008:184195 USPATFULL <>LOGINID::20081023>>
TI 5-Substituted quinazolinone derivatives and compositions comprising and methods of using the same
IN Muller, George W., Bridgewater, NJ, UNITED STATES
Man, Hon-Wah, Princeton, NJ, UNITED STATES
PI US 20080161328 A1 20080703
AI US 2007-904551 A1 20070926 (11)
PRAI US 2006-847471P 20060926 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3936
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are 5-substituted quinazolinone compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 132 USPATFULL on STN
AN 2008:184184 USPATFULL <<LOGINID::20081023>>
TI Inhibitors of Akt activity
IN Kelly, Michael J., Wayne, PA, UNITED STATES
Layton, Mark E., Harleysville, PA, UNITED STATES
Sanderson, Philip E., Valley Forge, PA, UNITED STATES
PI US 20080161317 A1 20080703
AI US 2007-999234 A1 20071204 (11)
PRAI US 2006-873198P 20061206 (60)
US 2007-967872P 20070906 (60)
US 2007-880661P 20070116 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ, 07065-0907, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1-6
DRWN No Drawings
LN.CNT 4149

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 132 USPATFULL on STN
AN 2008:166683 USPATFULL <<LOGINID::20081023>>
TI Isoindoline compounds and methods of their use
IN Muller, George W., Bridgewater, NJ, UNITED STATES
Man, Hon-Wah, Princeton, NJ, UNITED STATES
PA Celgene Corporation (U.S. corporation)
PI US 20080145336 A1 20080619
AI US 2008-70322 A1 20080215 (12)
RLI Division of Ser. No. US 2004-900332, filed on 28 Jul 2004, PENDING
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1-3
DRWN No Drawings
LN.CNT 2436

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel isoindoline compounds are disclosed. Methods of treating , preventing and/or managing cancer, diseases and disorders associated with, or characterized by, undesired angiogenesis, and diseases and disorders mediated by PDE 4, using the compounds are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 132 USPATFULL on STN
AN 2008:160175 USPATFULL <<LOGINID::20081023>>
TI INHIBITORS OF BRUTON'S TYROSINE KINASE
IN HONIGBERG, Lee, San Francisco, CA, UNITED STATES
VERNER, Erik, Belmont, CA, UNITED STATES
PAN, Zhengying, Alpharetta, GA, UNITED STATES
PA PHARMACYCLICS, INC., Sunnyvale, CA, UNITED STATES (U.S. corporation)

P1 US 20080139582 A1 20080612
AI US 2007-964285 A1 20071226 (11)
RLI Continuation-in-part of Ser. No. US 2007-692870, filed on 28 Mar 2007,
PENDING Continuation-in-part of Ser. No. US 2006-617645, filed on 28 Dec
2006, PENDING
PRAI US 2006-826720P 20060922 (60)
US 2006-828590P 20061006 (60)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA,
94304-1050, US
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 4949

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 132 USPATFULL on STN
AN 2008:158890 USPATFULL <>LOGINID::20081023>>
TI Bechet's disease using cyclopropyl-N-carboxamide
IN Zeldis, Jerome B., Princeton, NJ, UNITED STATES
PA Celgene Corporation (U.S. corporation)
PI US 20080138295 A1 20080612
AI US 2008-69473 A1 20080211 (12)
RLI Division of Ser. No. US 2005-534325, filed on 12 Sep 2005, Pat. No. US
7354948
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 14
ECL Exemplary Claim: 1-32
DRWN No Drawings
LN.CNT 2769

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of a selective cytokine inhibitory drug. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 132 USPATFULL on STN
AN 2008:152244 USPATFULL <>LOGINID::20081023>>

TI Methods for Treating Cancers Using Polymorphic Forms of
3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione
IN Zeldis, Jerome B., Princeton, NJ, UNITED STATES
Jaworsky, Markian S., Hopewell, NJ, UNITED STATES
Muller, George W., Bridgewater, NJ, UNITED STATES
Cameron, Louise M., Nazareth, PA, UNITED STATES
Chen, Roger Shen-Chu, Edison, NJ, UNITED STATES
Saindane, Manohar T., Monmouth Junction, NJ, UNITED STATES

PA Celgene Corporation (U.S. corporation)

PI US 20080132541 Al 20080605

AI US 2004-557302 Al 20040505 (10)

WO 2004-US14004 20040505

20070906 PCT 371 date

PRAI US 2003-10438213 20030515

US 2003-10704237 20031106

DT Utility

FS APPLICATION

LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US

CLMN Number of Claims: 36

ECL Exemplary Claim: 1-32

DRWN 1 Drawing Page(s)

LN.CNT 2735

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 132 USPATFULL on STN
AN 2008:131093 USPATFULL <<LOGINID::20081023>>

TI Diphenylethylen compounds and uses thereof

IN Muller, George W., Bridgewater, NJ, UNITED STATES

Payvandi, Faribourz, Belle Mead, NJ, UNITED STATES

Zhang, Ling H., Parsippany, NJ, UNITED STATES

Robarge, Michael J., Burton, OH, UNITED STATES

Chen, Roger, Edison, NJ, UNITED STATES

Man, Hon-Wah, Princeton, NJ, UNITED STATES

PA Celgene Corporation (U.S. corporation)

PI US 20080114061 Al 20080515

AI US 2007-983179 Al 20071107 (11)

RLI Division of Ser. No. US 2004-794931, filed on 5 Mar 2004, GRANTED, Pat. No. US 7312241

PRAI US 2003-452460P 20030305 (60)

DT Utility

FS APPLICATION

LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 7619

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to Diphenylethylen Compounds and compositions comprising a Diphenylethylen Compound. The present

invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more Diphenylethylene Compounds. In particular, the invention relates to methods for preventing or treating cancer or an inflammatory disorder by administering to a subject in need thereof one or more Diphenylethylene Compounds. The present invention further relates to articles of manufacture and kits comprising one or more Diphenylethylene Compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 132 USPATFULL on STN
AN 2008:124838 USPATFULL <<LOGINID::20081023>>
TI INHIBITORS OF BRUTON'S TYROSINE KINASE
IN Honigberg, Lee, San Francisco, CA, UNITED STATES
Verner, Erik, San Mateo, CA, UNITED STATES
Pan, Zhengying, Alpharetta, GA, UNITED STATES
PA PHARMACYCLICS, INC., Sunnyvale, CA, UNITED STATES (U.S. corporation)
PI US 20080108636 A1 20080508
AI US 2006-617645 A1 20061228 (11)
PRAI US 2006-826720P 20060922 (60)
US 2006-828590P 20061006 (60)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA,
94304-1050, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 4983

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 132 USPATFULL on STN
AN 2008:104412 USPATFULL <<LOGINID::20081023>>
TI Triazole compounds that modulate HSP90 activity
IN Ying, Weiwen, Ayer, MA, UNITED STATES
James, David, Cambridge, MA, UNITED STATES
Zhang, Shijie, Nashua, NH, UNITED STATES
Chae, Junghyun, Youngdengpo-gu, KOREA, REPUBLIC OF
Przewloka, Teresa, Tewksbury, MA, UNITED STATES
Ng, Howard P., Belmont, MA, UNITED STATES
Li, Hao, Brookline, MA, UNITED STATES
Demko, Zachary, Somerville, MA, UNITED STATES
Chimmanamada, Dinesh U., Arlington, MA, UNITED STATES
Lee, Chi-wan, Grafton, MA, UNITED STATES
Du, Zhenjian, Northborough, MA, UNITED STATES
Foley, Kevin, Waltham, MA, UNITED STATES
Song, Minghu, Waltham, MA, UNITED STATES
Sun, Lijun, Harvard, MA, UNITED STATES
Koya, Keizo, Chestnut Hill, MA, UNITED STATES

Zhou, Dan, Lexington, MA, UNITED STATES
Qin, Shuzhen, West Roxbury, MA, UNITED STATES
PI US 20080090887 A1 20080417
AI US 2007-807201 A1 20070525 (11)
PRAI US 2006-808425P 20060525 (60)
US 2006-808248P 20060525 (60)
US 2006-808256P 20060525 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133, US
CLMN Number of Claims: 126
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 12242
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hep90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 22 OF 132 USPATFULL on STN
AN 2008:87721 USPATFULL <>LOGINID::20081023>>
TI INHIBITORS OF BRUTON'S TYROSINE KINASE
IN Honigberg, Lee, San Francisco, CA, UNITED STATES
Verner, Erik, San Mateo, CA, UNITED STATES
Pan, Zhengying, Alpharetta, GA, UNITED STATES
PA PHARMACYCLICS, INC., Sunnyvale, CA, UNITED STATES (U.S. corporation)
PI US 20080076921 A1 20080327
AI US 2007-692870 A1 20070328 (11)
RLI Continuation-in-part of Ser. No. US 2006-617645, filed on 28 Dec 2006,
PENDING
PRAI US 2006-826720P 20060922 (60)
US 2006-828590P 20061006 (60)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA,
94304-1050, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 5018
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 132 USPATFULL on STN

AN 2008:58505 USPATFULL <<LOGINID::20081023>>
TI Therapeutic Use for a Group of Sulphated Polysaccharides
IN Vila Pabi, Francisco Javier, Barcelona, SPAIN
Escaich Ferrer, Josep, Barcelona, SPAIN
Verbruggen, August Lodewijk, Barcelona, SPAIN
Verges Milano, Josep, Corbera de Llobregat, SPAIN
Ruhi Roura, Ramon, Barcelona, SPAIN
Alaez Verson, Carlos Raul, Barcelona, SPAIN
PA Bioiberica, S.A., Barcelona, SPAIN (non-U.S. corporation)
PI US 20080051350 A1 20080228
AI US 2005-590311 A1 20050211 (10)
WO 2005-EP1390 20050211
20060823 PCT 371 date
PRAI ES 2004-464 20040227
DT Utility
FS APPLICATION
LREP VENABLE LLP, P.O. BOX 34385, WASHINGTON, DC, 20043-9998, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 709

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the use of a sulphated polysaccharide in acid form or as a physiologically acceptable salt thereof, selected from the group consisting of inulin sulphate, gellan sulphate, pullulan sulphate, curdian sulphate, alginic acid sulphate, laminarin sulphate, and pectin sulphate, for the preparation of a medicament for the treatment or prophylaxis of arthrosis in a mammal. Preferably, the sulphated polysaccharide is inulin sulphate, most preferably inulin polysulphate sodium salt. The present invention also relates to the use of a sulphated oligosaccharide derived from a polysaccharide selected from the group consisting of inulin, gellan, pullulan, curdian, alginic acid, laminarin, and pectin, for the preparation of a medicament for the treatment or prophylaxis of arthrosis in a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 132 USPATFULL on STN
AN 2008:44803 USPATFULL <<LOGINID::20081023>>
TI INHIBITORS OF TYROSINE KINASES AND USES THEREOF
IN Jankowski, Orion D., Burlingame, CA, UNITED STATES
Palmer, James T., Eltham, AUSTRALIA
Honigberg, Lee, San Francisco, CA, UNITED STATES
PA PHARMACYCLICS, INC., Sunnyvale, CA, UNITED STATES (U.S. corporation)
PI US 20080039426 A1 20080214
AI US 2006-617651 A1 20061228 (11)
PRAI US 2006-758617P 20060113 (60)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA,
94304-1050, US
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7263

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are

disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 132 USPATFULL on STN
AN 2008:30827 USPATFULL <>LOGINID::20081023>>
TI (+)-2-[1-(3-Ethoxy-4methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:methods of using and compositions thereof
IN Muller, George W., Bridgewater, NJ, UNITED STATES
Schafer, Peter H., Somerset, NJ, UNITED STATES
Man, Hon-Wah, Princeton, NJ, UNITED STATES
Ge, Chuansheng, Belle Mead, NJ, UNITED STATES
PA Celgene Corporation (U.S. corporation)
PI US 20080027123 A1 20080131
AI US 2007-824523 A1 20070629 (11)
RLI Division of Ser. No. US 2005-170308, filed on 28 Jun 2005, PENDING
Division of Ser. No. US 2003-392195, filed on 19 Mar 2003, GRANTED, Pat. No. US 6962940
PRAI US 2002-366515P 20020320 (60)
US 2003-438450P 20030107 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 12
ECL Exemplary Claim: 1-55
DRWN 2 Drawing Page(s)
LN.CNT 1800
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (-) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF- α or the inhibition of PDE4.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 26 OF 132 USPATFULL on STN
AN 2008:24382 USPATFULL <>LOGINID::20081023>>
TI Hydrogel-based joint repair system and method
IN Chudzik, Stephen J., St. Paul, MN, UNITED STATES
PA SurModics, Inc. (U.S. corporation)
PI US 20080021563 A1 20080124
AI US 2007-821466 A1 20070622 (11)
PRAI US 2006-816131P 20060623 (60)
US 2007-925275P 20070419 (60)
DT Utility
FS APPLICATION
LREP KAGAN BINDER, PLLC, SUITE 200, MAPLE ISLAND BUILDING, 221 MAIN STREET NORTH, STILLWATER, MN, 55082, US
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)

LN.CNT 1718

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a system and method for treating an orthopedic condition using a hydrogel-forming composition, which forms a hydrogel in situ at a target location and at least bio-mechanically treats the condition. The invention also provides a hydrogel forming composition designed to form a hydrogel with desirable biocompatible and biomechanical properties. In some aspects the hydrogel is formed in a water-permeable casing, which is delivered to an orthopedic joint in a minimally invasive manner. In particular, the system and method can be used for intervertebral disc replacement or repair.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 132 USPATFULL on STN
AN 2008:17555 USPATFULL <<LOGINID::20081023>>
TI Inhibitors of Akt Activity
IN Barnett, Stanley F., North Wales, PA, UNITED STATES
Bogusky, Michael J., Perkasie, PA, UNITED STATES
Leister, William H., Quakertown, PA, UNITED STATES
Lindsley, Craig W., Schwenksville, PA, UNITED STATES
PI US 20080015212 A1 20080117
AI US 2005-791418 A1 20051128 (11)
WO 2005-US43361 20051128
20070523 PCT 371 date

PRAI US 2004-632490P 20041202 (60)

DT Utility

FS APPLICATION

LREP MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ, 07065-0907, US

CLMN Number of Claims: 7

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2167

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant invention provides for canthine analogs that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 132 USPATFULL on STN
AN 2008:11083 USPATFULL <<LOGINID::20081023>>
TI Inhibitors of Akt Activity
IN Cosford, Nicholas D.P., San Diego, CA, UNITED STATES
Layton, Mark E., Harleysville, PA, UNITED STATES
Liang, Jun, Palo Alto, NJ, UNITED STATES
Lindsley, Craig W., Schwenksville, PA, UNITED STATES
Sanderson, Philip E., Valley Forge, PA, UNITED STATES
Zhao, Zhijian, Wilmington, DE, UNITED STATES
PI US 20080009507 A1 20080110
AI US 2006-795156 A1 20060210 (11)
WO 2006-US4715 20060210
20070712 PCT 371 date

PRAI US 2005-652737P 20050214 (60)

DT Utility

FS APPLICATION

LREP MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ, 07065-0907, US

CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2465

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 29 OF 132 USPATFULL on STN
AN 2008:10289 USPATFULL <>LOGINID::20081023>>
TI Tyrosine kinase inhibitors
IN Dinsmore, Christopher J., Schwenksville, PA, UNITED STATES
Beshore, Douglas C., Harleysville, PA, UNITED STATES
Bergman, Jeffrey M., Perkasie, NJ, UNITED STATES
Lindsay, Craig W., Schwenksville, PA, UNITED STATES
PI US 20080008708 A1 20080110
AI US 2007-890755 A1 20070807 (11)
RLI Continuation of Ser. No. US 2005-523286, filed on 3 Feb 2005, PENDING A
371 of International Ser. No. WO 2003-US24393, filed on 5 Aug 2003
PRAI US 2002-402482P 20020809 (60)
DT Utility
FS APPLICATION
LREP MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ, 07065-0907, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4297

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises an indole-sulfonamide moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 30 OF 132 USPATFULL on STN
AN 2008:5099 USPATFULL <>LOGINID::20081023>>
TI Triazole compounds that modulate HSP90 activity
IN Chimmanamada, Dinesh U., Arlington, MA, UNITED STATES
Ying, Weiwen, Ayer, MA, UNITED STATES
Przewloka, Teresa, Tewksbury, MA, UNITED STATES
Zhang, Shijie, Nashua, NH, UNITED STATES
Foley, Kevin, Waltham, MA, UNITED STATES
Du, Zhenjian, Northborough, MA, UNITED STATES
Zhou, Dan, Lexington, MA, UNITED STATES
Qin, Shuzhen, West Roxbury, MA, UNITED STATES
PI US 20080004277 A1 20080103
AI US 2007-807331 A1 20070525 (11)
PRAI US 2006-808251P 20060525 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX

9133, CONCORD, MA, 01742-9133, US
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7147

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 31 OF 132 USPATFULL on STN
AN 2008:5093 USPATFULL <>LOGINID::20081023>>
TI Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith
IN McKenna, Jeffrey M., Horsham, UNITED KINGDOM
Papa, Patrick W., Carlsbad, CA, UNITED STATES
Sakata, Steven T., San Diego, CA, UNITED STATES
Erdman, Paul E., San Diego, CA, UNITED STATES
Packard, Garrick K., San Diego, CA, UNITED STATES
PI US 20080004271 A1 20080103
AI US 2007-654344 A1 20070116 (11)
PRAI US 2006-759819P 20060117 (60)
US 2006-814862P 20060619 (60)
US 2006-818246P 20060630 (60)
US 2006-854637P 20061025 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 10585

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided herein are compounds having TNF α and/or PDE4 and/or B-RAF inhibitory activity, and compositions thereof. In particular, provided herein are compounds of the formula I: ##STR1##

and pharmaceutically acceptable salts, solvates, hydrates, clathrates, stereoisomers, polymorphs and prodrugs thereof, wherein Ar, R.^{sup.1}, R.^{sup.2}, R.^{sup.3}, R.^{sup.4}, n and Z are as described herein. Further provided herein are methods for treating or preventing various diseases and disorders by administering to a patient one or more TNF α and/or PDE4 and/or B-RAF inhibitors. In particular, provided herein are methods for preventing or treating cancer, inflammatory disorders, cognition and memory disorders and autoimmune disorders, or one or more symptoms thereof by administering to a patient one or more TNF α and/or PDE4 and/or B-RAF inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 32 OF 132 USPATFULL on STN
AN 2007:329152 USPATFULL <>LOGINID::20081023>>
TI Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
IN Ralston, Robert O. II, Union, NJ, UNITED STATES

Strizki, Julie M., Yardley, PA, UNITED STATES
Vlach, Jaromir, Annandale, NJ, UNITED STATES
Gupta, Samir K., East Brunswick, NJ, UNITED STATES
O'Mara, Edward M. JR., Skillman, NJ, UNITED STATES
Ghosal, Anima, Edison, NJ, UNITED STATES
Treitel, Michelle A., New York, NY, UNITED STATES
McLeod, James F., Morris Township, NJ, UNITED STATES
White, Ronald E., Cranbury, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20070287664 AI 20071213
AI US 2007-725518 AI 20070319 (11)
PRAI US 2006-785761P 20060323 (60)
US 2006-809713P 20060531 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLough CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000
GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
CLMN Number of Claims: 78
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 7207
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are medicaments, pharmaceutical compositions, pharmaceutical
kits, and methods based on combinations comprising, separately or
together: (a) a CYP3A4 inhibitor; and (b) a HCV protease inhibitor; for
concurrent or consecutive administration in treating a human
subject infected with HCV.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 33 OF 132 USPATFULL on STN
AN 2007:322602 USPATFULL <>(LOGINID::20081023>>
TI INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE
IN Buggy, Joseph J., Mountain View, CA, UNITED STATES
Balasubramanian, Sriram, San Carlos, CA, UNITED STATES
Verner, Erik, San Mateo, CA, UNITED STATES
Tai, Vincent W.F., San Mateo, CA, UNITED STATES
Lee, Chang-Sun, Belle Mead, NJ, UNITED STATES
PA PHARMACYCLICS, INC., Sunnyvale, CA, UNITED STATES (U.S. corporation)
PI US 20070281934 AI 20071206
AI US 2007-687565 AI 20070316 (11)
PRAI US 2006-783287P 20060316 (60)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA,
94304-1050, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 7284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Described herein are compounds and pharmaceutical compositions
containing such compounds, which inhibit the activity of histone
deacetylase 8 (HDAC8). Also described herein are methods of using such
HDAC8 inhibitors, alone and in combination with other compounds, for
treating diseases or conditions that would benefit from
inhibition of HDAC8 activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 34 OF 132 USPATFULL on STN

AN 2007:314754 USPATFULL <>LOGINID::20081023>>
TI Combinations comprising HCV protease inhibitor(s) and HCV polymerase
inhibitor(s), and methods of treatment related thereto
IN Tong, Xiao, East Brunswick, NJ, UNITED STATES
Malcolm, Bruce A., Paoli, PA, UNITED STATES
Huang, Hsueh-Cheng, Berkeley Heights, NJ, UNITED STATES
PI US 20070274951 Al 20071129
AI US 2007-705087 Al 20070209 (11)
PRAI US 2006-771927P 20060209 (60)
US 2006-841298P 20060830 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLough CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000
GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
CLMN Number of Claims: 62
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 6308
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are medicaments, pharmaceutical compositions, pharmaceutical
kits, and methods based on combinations of at least one HCV protease
inhibitor and at least one HCV polymerase inhibitor but not HCV-796; for
concurrent or consecutive administration in treating or
ameliorating one or more symptoms of HCV, or disorders associated with
HCV in a subject in need thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 35 OF 132 USPATFULL on STN
AN 2007:303296 USPATFULL <>LOGINID::20081023>>
TI (S)-N-methylalnatrexone
IN Boyd, Thomas A., Grandview, NY, UNITED STATES
Wagoner, Howard, Warwick, NY, UNITED STATES
Sanghi, Suketu P., Kendall Park, NJ, UNITED STATES
Verbicky, Christopher, Broadalbin, NY, UNITED STATES
Andruski, Stephen, Clifton Park, NY, UNITED STATES
PI US 20070265293 Al 20071115
AI US 2006-441452 Al 20060525 (11)
PRAI US 2005-684570P 20050525 (60)
DT Utility
FS APPLICATION
LREP WOLE GREENFIELD & SACKS, P.C., 600 ATLANTIC AVENUE, BOSTON, MA,
02210-2206, US
CLMN Number of Claims: 78
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 3572
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to S-MNTX, methods of producing S-MNTX,
pharmaceutical preparations comprising S-MNTX and methods for their use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 36 OF 132 USPATFULL on STN
AN 2007:291243 USPATFULL <>LOGINID::20081023>>
TI 7-amido-isoindolyl compounds and methods of its use
IN Man, Hon-Wah, Princeton, NJ, UNITED STATES
Muller, George W., Bridgewater, NJ, UNITED STATES
Zhang, Weihong, Highland Park, NJ, UNITED STATES
PA Celgene Corporation. (U.S. corporation)
PI US 20070254942 Al 20071101

AI US 2007-818927 A1 20070615 (11)
RLI Division of Ser. No. US 2005-250408, filed on 17 Oct 2005, GRANTED, Pat.
No. US 7256210 Division of Ser. No. US 2004-798317, filed on 12 Mar
2004, GRANTED, Pat. No. US 7034052
PRAI US 2003-454155P 20030312 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1-45
DRWN No Drawings
LN.CNT 3431

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention encompasses 7-amido-isindolyl compounds and methods of
using these compounds and compositions in mammals for treatment
, prevention or management of various diseases and disorders. Examples
include, but are not limited to, cancer, inflammatory bowel disease and
myelodysplastic syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 37 OF 132 USPATFULL on STN
AN 2007:278749 USPATFULL <<LOGINID::20081023>>
TI Isoindoline compounds and methods of making and using the same
IN Muller, George W., Bridgewater, NJ, UNITED STATES
Man, Hon-Wan, Princeton, NJ, UNITED STATES
PA Celgene Corporation (U.S. corporation)
PI US 20070244183 A1 20071018
AI US 2007-820788 A1 20070619 (11)
RLI Division of Ser. No. US 2004-900270, filed on 28 Jul 2004, GRANTED, Pat.
No. US 7244759
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2396

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention encompasses isoindoline compounds, pharmaceutical
compositions comprising them, and methods of their use for the
treatment, prevention or management of various diseases and
disorders. Examples include, but are not limited to, cancer,
inflammatory bowel disease and myelodysplastic syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 38 OF 132 USPATFULL on STN
AN 2007:278694 USPATFULL <<LOGINID::20081023>>
TI 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
IN HUTCHINSON, John Howard, La Jolla, CA, UNITED STATES
King, Christopher David, Carlsbad, CA, UNITED STATES
Seiders, Thomas Jon, San Diego, CA, UNITED STATES
PA AMIRA PHARMACEUTICALS, INC., San Diego, CA, UNITED STATES (U.S.
corporation)
PI US 20070244128 A1 20071018
AI US 2007-745387 A1 20070507 (11)
RLI Continuation-in-part of Ser. No. US 2006-553946, filed on 27 Oct 2006,
PENDING Continuation-in-part of Ser. No. WO 2006-US42690, filed on 30
Oct 2006, PENDING Continuation-in-part of Ser. No. WO 2006-US43095,
filed on 3 Nov 2006, PENDING Continuation-in-part of Ser. No. WO

PRAI 2006-US43108, filed on 3 Nov 2006, PENDING
US 2005-734030P 20051104 (60)
US 2006-747174P 20060512 (60)
US 2006-823344P 20060823 (60)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA,
94304-1050, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 5801

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 39 OF 132 USPATFULL on STN
AN 2007:271592 USPATFULL <>LOGINID::20081023>>
TI Controlled-release formulation of HCV protease inhibitor and methods using the same
IN Malcolm, Bruce A., Paoli, PA, UNITED STATES
Cho, Wing-Kee Philip, Princeton, NJ, UNITED STATES
Alton, Kevin B., Cedar Knolls, NJ, UNITED STATES
Qiu, Zhihui, Bridgewater, NJ, UNITED STATES
Wan, Jiansheng, Springfield, NJ, UNITED STATES
Monteith, David, Pittstown, NJ, UNITED STATES
PI US 20070237818 A1 20071011
AI US 2006-636701 A1 20061207 (11)
RLI Continuation-in-part of Ser. No. US 2006-443905, filed on 31 May 2006, PENDING
PRAI US 2005-686861P 20050602 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
CLMN Number of Claims: 52
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 8318

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Controlled-release dosage formulations including at least one compound of Formulae I to XXVIII herein and a controlled-release carrier and methods of treatment using the same are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 40 OF 132 USPATFULL on STN
AN 2007:265450 USPATFULL <>LOGINID::20081023>>
TI Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
IN Ghosal, Anima, Edison, NJ, UNITED STATES
Kishnani, Narendra S., East Brunswick, NJ, UNITED STATES
Alton, Kevin B., Cedar Knolls, NJ, UNITED STATES
White, Ronald E., Cranbury, NJ, UNITED STATES

P1 US 20070232527 A1 20071004
AI US 2006-502562 A1 20060810 (11)
RLI Continuation-in-part of Ser. No. US 2006-443647, filed on 31 May 2006,
PENDING
PRAI US 2005-686924P 20050602 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000
GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US
CLMN Number of Claims: 69
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 7105

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are medicaments, pharmaceutical compositions, pharmaceutical
kits, and methods based on combinations of a hepatitis C virus (HCV)
protease inhibitor and an aldo-keto reductase (AKR) competitor, for
concurrent or consecutive administration in treating,
preventing, or ameliorating one or more symptoms of HCV,
treating disorders associated with HCV, or inhibiting cathepsin
activity in a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 41 OF 132 USPATFULL on STN
AN 2007:257340 USPATFULL <>LOGINID::20081023>>
TI 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
IN Hutchinson, John Howard, La Jolla, CA, UNITED STATES
Wang, Bowei, San Diego, CA, UNITED STATES
Stock, Nicholas Simon, San Diego, CA, UNITED STATES
Seiders, Thomas Jon, San Diego, CA, UNITED STATES
PA AMIRA PHARMACEUTICALS, INC., San Diego, CA, UNITED STATES, 92121 (U.S.
corporation)
PI US 20070225285 A1 20070927
AI US 2007-746010 A1 20070508 (11)
RLI Continuation-in-part of Ser. No. US 2006-553946, filed on 27 Oct 2006,
PENDING Continuation-in-part of Ser. No. WO 2006-US43095, filed on 3 Nov
2006, PENDING Continuation-in-part of Ser. No. WO 2006-US42690, filed on
30 Oct 2006, PENDING Continuation-in-part of Ser. No. WO 2006-US43018,
filed on 3 Nov 2006, PENDING Continuation of Ser. No. US 2006-483193,
filed on 7 Jul 2006, GRANTED, Pat. No. US 7250816

PRAI US 2005-734030P 20051104 (60)
US 2006-747174P 20060512 (60)
US 2006-823344P 20060823 (60)
US 2005-734030P 20051104 (60)
US 2006-747174P 20060512 (60)
US 2006-823344P 20060823 (60)
US 2005-734030P 20051104 (60)
US 2006-747174P 20060512 (60)
US 2006-823344P 20060823 (60)

DT Utility

FS APPLICATION

LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA,
94304-1050, US

CLMN Number of Claims: 26

ECL Exemplary Claim: 1

DRWN 14 Drawing Page(s)

LN.CNT 11279

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described herein are compounds and pharmaceutical compositions
containing such compounds, which modulate the activity of

5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 42 OF 132 USPATFULL on STN
AN 2007:250569 USPATFULL <>LOGINID::20081023>>
TI 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
IN Hutchinson, John Howard, La Jolla, CA, UNITED STATES
Prasit, Petpiboon Peppi, Rancho Santa Fe, CA, UNITED STATES
Moran, Mark, Orinda, CA, UNITED STATES
Evans, Jillian F., Carlsbad, CA, UNITED STATES
Stearns, Brian Andrew, San Diego, CA, UNITED STATES
Roppe, Jeffrey Roger, Temecula, CA, UNITED STATES
Wang, Bowei, San Diego, CA, UNITED STATES
Truong, Yen Pham, San Diego, CA, UNITED STATES
Li, Yiwei, San Diego, CA, UNITED STATES
Zunic, Jasmine Eleanor, San Diego, CA, UNITED STATES
Arruda, Jeannie M., San Diego, CA, UNITED STATES
Stock, Nicholas Simon, San Diego, CA, UNITED STATES
Haddach, Mustapha, San Diego, CA, UNITED STATES
Seiders, Thomas Jon, San Diego, CA, UNITED STATES
Scott, Jill Melissa, San Diego, CA, UNITED STATES
PA AMIRA PHARMACEUTICALS, INC., San Diego, CA, UNITED STATES, 92121 (U.S.
corporation)
PI US 20070219206 A1 20070920
AI US 2007-744555 A1 20070504 (11)
RLI Continuation-in-part of Ser. No. US 2006-553946, filed on 27 Oct 2006,
PENDING
PRAI US 2005-734030P 20051104 (60)
US 2006-747174P 20060512 (60)
US 2006-823344P 20060823 (60)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA,
94304-1050, US
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 16696

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.